PriceTargets.com logo

Novartis - NVS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $114.00
  • Forecasted Upside: 20.80%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$94.37 As of 04/19/2024 01:00 AM ET
▲ +1.8 (1.94%)

This chart shows the closing price for NVS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novartis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVS

Analyst Price Target is $114.00
▲ +20.80% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Novartis in the last 3 months. The average price target is $114.00, with a high forecast of $114.00 and a low forecast of $114.00. The average price target represents a 20.80% upside from the last price of $94.37.

This chart shows the closing price for NVS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in Novartis. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2024BMO Capital MarketsInitiated CoverageMarket Perform$114.00Low
1/23/2024Morgan StanleyInitiated CoverageEqual Weight$114.00Low
12/18/2023HSBCDowngradeBuy ➝ HoldLow
9/25/2023Morgan StanleyUpgradeUnderweight ➝ Equal WeightLow
7/14/2023HSBCInitiated CoverageBuyLow
4/26/2023Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyLow
4/19/2023BTIG ResearchBoost Target$75.00 ➝ $85.00Low
3/27/2023Deutsche Bank AktiengesellschaftUpgradeSell ➝ HoldLow
1/26/2023CitigroupDowngradeBuy ➝ NeutralLow
1/6/2023Morgan StanleyDowngradeEqual Weight ➝ UnderweightLow
1/3/2023JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralLow
12/14/2022UBS GroupBoost TargetNeutral ➝ NeutralCHF 82 ➝ CHF 84Low
12/5/2022Stifel NicolausUpgradeHold ➝ BuyN/A
10/26/2022JPMorgan Chase & Co.Lower TargetUnderweight ➝ UnderweightCHF 81 ➝ CHF 78Low
10/14/2022BarclaysLower TargetCHF 85 ➝ CHF 75Low
10/7/2022Deutsche Bank AktiengesellschaftLower TargetSell ➝ SellCHF 75 ➝ CHF 70Low
9/29/2022Oddo BhfDowngradeOutperform ➝ NeutralCHF 88Low
9/15/2022Credit Suisse GroupDowngradeNeutral ➝ UnderperformLow
9/14/2022Berenberg BankDowngradeBuy ➝ HoldLow
9/8/2022Morgan StanleyLower TargetCHF 97 ➝ CHF 88Low
9/7/2022Kepler Capital MarketsUpgradeHold ➝ BuyCHF 90Low
7/20/2022JPMorgan Chase & Co.Boost TargetUnderweight ➝ UnderweightCHF 80 ➝ CHF 81Low
6/29/2022Deutsche Bank AktiengesellschaftLower TargetCHF 80 ➝ CHF 75Low
6/3/2022OppenheimerDowngradeOutperform ➝ Market PerformLow
5/9/2022Wolfe ResearchDowngradeOutperform ➝ Market PerformMedium
5/6/2022Morgan StanleyBoost TargetCHF 90 ➝ CHF 94Low
4/28/2022Credit Suisse GroupBoost TargetCHF 85 ➝ CHF 88Medium
4/27/2022UBS GroupBoost TargetNeutral ➝ NeutralCHF 85 ➝ CHF 88Medium
4/14/2022BarclaysBoost TargetCHF 80 ➝ CHF 85Low
4/8/2022UBS GroupBoost TargetCHF 84 ➝ CHF 85Low
2/28/2022Stifel NicolausInitiated CoverageHoldLow
2/3/2022Societe GeneraleLower TargetCHF 107 ➝ CHF 105Low
1/10/2022CitigroupInitiated CoverageBuyMedium
12/14/2021Redburn PartnersDowngradeBuy ➝ NeutralMedium
12/6/2021Exane BNP ParibasDowngradeOutperform ➝ NeutralCHF 85Low
12/6/2021BNP ParibasDowngradeOutperform ➝ NeutralMedium
12/3/2021Bryan, Garnier & CoReiterated RatingBuy ➝ Neutral$115.00 ➝ $85.00Low
11/5/2021UBS GroupDowngradeBuy ➝ NeutralLow
10/27/2021JPMorgan Chase & Co.Reiterated RatingUnderweightLow
10/12/2021Berenberg BankReiterated RatingBuyLow
10/8/2021UBS GroupReiterated RatingBuyLow
9/20/2021Deutsche Bank AktiengesellschaftDowngradeHold ➝ SellMedium
7/28/2021JPMorgan Chase & Co.Reiterated RatingUnderweightLow
7/22/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldLow
5/11/2021Morgan StanleyReiterated RatingOverweightLow
4/28/2021JPMorgan Chase & Co.Reiterated RatingUnderweightLow
4/28/2021Oddo BhfUpgradeNeutral ➝ OutperformLow
4/19/2021UBS GroupReiterated RatingBuyLow
3/23/2021Societe GeneraleReiterated RatingBuyLow
3/22/2021Sanford C. BernsteinInitiated CoverageMarket PerformMedium
3/16/2021ArgusReiterated RatingBuy ➝ HoldLow
3/10/2021ArgusDowngradeBuy ➝ HoldLow
2/2/2021Morgan StanleyReiterated RatingOverweightLow
2/1/2021CowenDowngradeOutperform ➝ Market Perform$110.00 ➝ $105.00Low
1/22/2021BarclaysReiterated RatingUnderweightMedium
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuyLow
1/8/2021Morgan StanleyReiterated RatingOverweightLow
12/3/2020ArgusBoost Target$100.00 ➝ $112.00Low
11/25/2020UBS GroupReiterated RatingBuyLow
11/10/2020JPMorgan Chase & Co.Reiterated RatingUnderweightLow
9/29/2020Berenberg BankInitiated CoverageBuyMedium
9/23/2020Oddo BhfDowngradeBuy ➝ NeutralLow
9/10/2020UBS GroupUpgradeNeutral ➝ BuyLow
9/1/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightHigh
8/12/2020JPMorgan Chase & Co.Reiterated RatingUnderweightLow
7/28/2020Morgan StanleyReiterated RatingEqual WeightLow
6/15/2020CitigroupUpgradeNeutral ➝ BuyLow
5/11/2020UBS GroupReiterated RatingNeutralMedium
4/29/2020JPMorgan Chase & Co.Reiterated RatingUnderweightLow
4/29/2020BarclaysReiterated RatingUnderweightLow
4/23/2020Morgan StanleyReiterated RatingEqual WeightLow
4/3/2020The Goldman Sachs GroupReiterated RatingBuy$116.00High
3/10/2020Morgan StanleyUpgradeUnderweight ➝ Equal WeightLow
2/25/2020GuggenheimDowngradeBuy ➝ NeutralHigh
2/17/2020CitigroupDowngradeBuy ➝ NeutralLow
10/25/2019CowenReiterated RatingBuy$100.00Low
8/29/2019Jefferies Financial GroupReiterated RatingBuyLow
7/23/2019ArgusBoost TargetBuy$105.00Low
7/23/2019Kepler Capital MarketsDowngradeBuy ➝ HoldLow
7/5/2019JPMorgan Chase & Co.Reiterated RatingSellMedium
4/25/2019Liberum CapitalUpgradeHold ➝ BuyLow
4/24/2019GuggenheimUpgradeNeutral ➝ Buy$79.16Medium
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 20 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
9/22/2023
  • 22 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
10/22/2023
  • 9 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2023
  • 14 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2023
  • 19 very positive mentions
  • 34 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/20/2024
  • 37 very positive mentions
  • 29 positive mentions
  • 6 negative mentions
  • 4 very negative mentions
Mentions as of
2/19/2024
  • 25 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/20/2024
  • 23 very positive mentions
  • 16 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 23 very positive mentions
  • 16 positive mentions
  • 6 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Novartis logo
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Read More

Today's Range

Now: $94.37
Low: $93.15
High: $94.49

50 Day Range

MA: $98.09
Low: $92.57
High: $103.90

52 Week Range

Now: $94.37
Low: $92.19
High: $108.78

Volume

2,338,264 shs

Average Volume

1,498,161 shs

Market Capitalization

$200.03 billion

P/E Ratio

13.14

Dividend Yield

2.61%

Beta

0.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Novartis?

The following sell-side analysts have issued stock ratings on Novartis in the last twelve months: BMO Capital Markets, BTIG Research, Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, Morgan Stanley, and StockNews.com.
View the latest analyst ratings for NVS.

What is the current price target for Novartis?

2 Wall Street analysts have set twelve-month price targets for Novartis in the last year. Their average twelve-month price target is $114.00, suggesting a possible upside of 20.8%. BMO Capital Markets has the highest price target set, predicting NVS will reach $114.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $114.00 for Novartis in the next year.
View the latest price targets for NVS.

What is the current consensus analyst rating for Novartis?

Novartis currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVS, but not buy more shares or sell existing shares.
View the latest ratings for NVS.

What other companies compete with Novartis?

Other companies that are similar to Novartis include Abbott Laboratories, AstraZeneca, Pfizer, Sanofi and AbbVie. Learn More about companies similar to Novartis.

How do I contact Novartis' investor relations team?

Novartis' physical mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company's listed phone number is (161) 324-1111 and its investor relations email address is [email protected]. The official website for Novartis is www.novartis.com. Learn More about contacing Novartis investor relations.